Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICPT shares.
View ICPT analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' shares. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they expect the company's share price to reach $25.70 in the next twelve months. This suggests a possible upside of 89.1% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.

Intercept Pharmaceuticals' stock was trading at $12.37 on January 1st, 2023. Since then, ICPT stock has increased by 9.9% and is now trading at $13.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ICPT earnings forecast.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.89. The biopharmaceutical company earned $92.80 million during the quarter, compared to analysts' expectations of $83.04 million. Intercept Pharmaceuticals's revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned ($2.01) earnings per share.

ETFs with the largest weight of Intercept Pharmaceuticals (NASDAQ:ICPT) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $310.00 million-$340.00 million, compared to the consensus revenue estimate of $321.92 million.

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.36%), Renaissance Technologies LLC (1.71%), Macquarie Group Ltd. (1.62%), Geode Capital Management LLC (1.41%), ExodusPoint Capital Management LP (1.28%) and Jupiter Asset Management Ltd. (1.02%). Insiders that own company stock include Christian Weyer, David A Ford, Jason Campagna, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends.

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICPT stock can currently be purchased for approximately $13.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $566.30 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.47 on an earnings per share basis.

The company employs 437 workers across the globe.

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.